Orange Book product · Brand (NDA)
JYLAMVO
METHOTREXATE
At a glance
Nov 29, 2022
Approved
Brand (NDA)
Application
Not listed
TE code
7
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Nov 29, 2022
3 yr 7 mo ago
Today
Patent 11771701 expires
Listed drug product patent expiration.
Oct 29, 2034
in 8 yr 6 mo
Patent 11771701 expires
Listed drug product patent expiration.
Oct 29, 2034
in 8 yr 6 mo
Patent 11771701 expires
Listed drug product patent expiration.
Oct 29, 2034
in 8 yr 6 mo
Patent 11771701 expires
Listed drug product patent expiration.
Oct 29, 2034
in 8 yr 6 mo
Patent 11771701 expires
Listed drug product patent expiration.
Oct 29, 2034
in 8 yr 6 mo
Patent 12605385 expires
Listed drug product patent expiration.
Oct 25, 2035
in 9 yr 6 mo
Patent 11129833 expires
Listed drug product patent expiration.
Oct 28, 2035
in 9 yr 6 mo
Pharmaceutical detail
Active ingredient
METHOTREXATE
Strength
2MG/ML
Dosage form
SOLUTION
Route
ORAL
TE code
Not listed
Application
NDA 212479
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (7)
| Patent | Expires | In | Type |
|---|---|---|---|
| 11771701 | Oct 29, 2034 | in 8 yr 6 mo | ProductU-3700 |
| 11771701 | Oct 29, 2034 | in 8 yr 6 mo | ProductU-3701 |
| 11771701 | Oct 29, 2034 | in 8 yr 6 mo | ProductU-3702 |
| 11771701 | Oct 29, 2034 | in 8 yr 6 mo | ProductU-3703 |
| 11771701 | Oct 29, 2034 | in 8 yr 6 mo | ProductU-3704 |
| 12605385 | Oct 25, 2035 | in 9 yr 6 mo | Product |
| 11129833 | Oct 28, 2035 | in 9 yr 6 mo | Product |
